TP53 and angiosarcoma: Finally, in contrast to intrathyroidal angiosarcomas that, overall, harbor a low mutational burden, anaplastic thyroid carcinomas display a complex genomic landscape with frequent TP53 (40–80%) and TERT promoter (30–75%) aberrations, together with RAS and BRAF V600E (10–50% each) mutations among others [73, 75].